Estrategia en Cardiopatía Isquémica del Sistema Nacional de Salud

Objectives

Spain’s Strategy for Ischaemic Heart Disease within the National Health System provides a nationally coordinated framework to prevent coronary disease, improve equitable and high-quality care, support rehabilitation, strengthen research and assess progress. It was approved by the Interterritorial Council of the National Health System on 28 June 2006 and builds on the 2003 Comprehensive Plan for Ischaemic Heart Disease.[1][2]It aims to reduce avoidable mortality, morbidity, disability and inequalities associated with ischaemic heart disease across Spain.[3][4]

• Promote health and prevent disease by reducing tobacco use, obesity, unhealthy diets, physical inactivity, harmful alcohol consumption and psychosocial risks, while addressing common determinants shared with other chronic diseases.[5][6][7]
• Detect and manage cardiovascular risk factors, including smoking, hypertension, dyslipidaemia, diabetes and obesity, through structured clinical recording, opportunistic case-finding and risk-stratified preventive or therapeutic action.[8][9][10]
• Improve acute coronary syndrome care by reducing delays to seeking help, defibrillation, electrocardiography, reperfusion and revascularisation.[11][12]
• Strengthen chronic coronary care for stable angina, ischaemic left-ventricular dysfunction, ventricular arrhythmias and sudden cardiac death, with coordinated follow-up across primary, specialist and emergency care.[13][14]
• Ensure timely and equitable access to coronary angiography, revascularisation, cardiac transplantation and relevant specialist technologies irrespective of residence.[15][16][17]
• Provide lifelong secondary prevention and cardiac rehabilitation, supporting risk-factor control, physical and psychological recovery, social reintegration and return to usual life.[18][19][20]
• Develop information systems and research capacity to measure population burden, care quality, outcomes, disparities and the effectiveness of interventions.[21][22][23]

The strategy is grounded in solidarity, equity and participation, and seeks common service standards while allowing autonomous communities to implement locally agreed measures suited to their needs and resources.[4]Cardiovascular disease represented a major health need, accounting for 125,723 deaths and 35% of all deaths in Spain in 2000; ischaemic heart disease accounted for the largest share of cardiovascular deaths.[24]

Implementation

Implementation combines national coordination with autonomous-community delivery, using evidence-informed standards, multidisciplinary working groups, care networks, clinical pathways, agreed indicators and periodic review.[25][4][26]Development involved the Ministry of Health and Consumer Affairs, autonomous communities, scientific societies, clinicians, managers, researchers, technical committees and external experts.[27][2][28][29]

• Coordinate national and regional action through the Interterritorial Council of the National Health System, which approves common approaches and supports implementation across autonomous communities.[1][4][30]
• Use prioritisation criteria covering evidence, expected impact, opportunity, feasibility and evaluability through National Health System information systems.[1][31]
• Deliver prevention through public information, professional training, school and workplace action, food-sector collaboration, regulation and community interventions adapted to age, sex and social context.[11][32][7]
• Organise risk-factor prevention primarily through accessible primary care, using clinical histories, standardised measurements, screening intervals and quantitative cardiovascular-risk assessment to tailor intervention intensity.[8][33][34][10]
• Establish acute coronary syndrome networks linking emergency coordination, ambulance services, primary care, referring hospitals and specialist centres, with advance notification, transfer protocols and access to primary angioplasty where indicated.[35][36][37][38]
• Develop integrated chronic-care and rehabilitation pathways between hospitals, primary care and outpatient cardiology, beginning during admission and continuing after discharge with shared protocols and patient information.[18][39][40][20]
• Support specialist quality assurance through activity registration, outcome evaluation, centre and professional accreditation, clinical-practice guidelines and evidence-based technology assessment.[38][41][19]
• Expand research networks, longitudinal population studies, disease registers and coordinated databases linking basic, clinical, epidemiological and health-services research.[42][43][44]

Monitoring operates at intervention-specific and whole-plan levels. The framework includes indicators for health behaviours, cardiovascular-risk detection and control, emergency response, treatment times, procedure outcomes, rehabilitation coverage, mortality, potential years of life lost and disease incidence.[26][45][46][47]Data sources include the National Health Survey, mortality statistics, hospital discharge Minimum Basic Data Sets, autonomous-community information systems, scientific-society registries, population registers and the National Death Index.[48][49][50][51][52]

Specified operational expectations include electrocardiography and initial risk stratification within 10 minutes of hospital arrival, fibrinolysis within 30 minutes of arrival or 90 minutes of the emergency call, and primary angioplasty within 90 minutes of hospital arrival.[53][12]The strategy also envisages biennial or annual reporting for several indicators and a situation analysis after the second year of progressive implementation, although detailed accountability arrangements are not consistently specified in the supplied material.[54][55][47]

No dedicated implementation budget is specified.[1][50]The source estimates direct and indirect costs of ischaemic heart disease in Spain at approximately 2,000 million euros annually in 2003, including productivity losses.[1]

Monitoring & Evaluation

The strategy establishes a national monitoring framework for ischaemic heart disease that combines strategic-line indicators, clinical records, routine administrative data, disease registries, surveys and research. It is intended to assess implementation, changes in risk factors, care quality, morbidity, mortality, disability and inequalities, with autonomous communities adapting implementation within a common National Health System approach.[25][26][55]

• Measure prevention through smoking prevalence, obesity, physical activity, dietary patterns, hypertension, diabetes and hypercholesterolaemia, using sources including the National Health Survey, Health Barometer, population examinations, nutrition studies and regional reports.[45]
• Monitor risk-factor detection and management in primary care, including the proportion of people with identified risk factors, documented cardiovascular-risk assessment, high-risk classification, smoking cessation, blood-pressure control, low-density lipoprotein cholesterol control, diabetes control and weight reduction.[48][45]
• Report primary-care detection of major cardiovascular risk factors biennially by autonomous community, age group and sex, and report cardiovascular-risk assessment among eligible adults on the same basis.[48]
• Track acute myocardial infarction incidence annually by autonomous community, age group and sex, using hospital discharges with acute myocardial infarction as the principal diagnosis and excluding readmissions.[49]
• Monitor crude and adjusted ischaemic-heart-disease mortality and potential years of life lost annually by autonomous community and sex, using death statistics and National Statistics Institute population projections.[49]
• Measure global impact through age- and sex-standardised mortality and potential years of life lost, with annual reporting and five-year periods used to assess trends.[45]
• Track health-promotion indicators biennially, including smoking, obesity and physical activity, disaggregated by autonomous community, sex and age group.[54][56]
• Assess whether autonomous communities have documented quality-monitoring systems for cardiovascular risk-factor care.[56][57]
• Monitor emergency-care performance through the delay from symptom onset to requesting help, defibrillator availability in basic life-support ambulances, time to first defibrillation-capable resource, and the existence of acute coronary syndrome and chronic ischaemic-heart-disease network maps.[56][30]
• Use clinical time targets for acute coronary syndrome, including electrocardiography and initial stratification within 10 minutes, fibrinolysis within 30 minutes of hospital arrival or 90 minutes of the emergency call, and primary angioplasty within 90 minutes of hospital arrival.[53][12]
• Assess revascularisation and transplantation quality through hospital mortality after angioplasty and coronary surgery, reintervention, arterial-graft use and one-year transplant mortality, with results disaggregated where specified by age and sex.[57][58][17]
• Monitor rehabilitation through the proportion of health areas with coordinated programmes and the proportion of discharged patients entering secondary prevention or cardiac rehabilitation.[58][47]
• Use national and scientific-society registries to capture procedure volumes, patient characteristics, treatment, complications, outcomes, technology use and resource information.[13][59]
• Strengthen information infrastructure through standardised indicator definitions, a unified National Health System identification code, primary- and specialist-care information systems, Minimum Basic Data Sets and progressively computerised clinical and administrative records.[26]
• Review implementation at two levels: assess each intervention area and assess overall implementation, risk-factor change and reductions in morbidity, mortality and disability; conduct a situation analysis after the second year because implementation is progressive.[26][55]

Data-quality limitations require cautious interpretation. Hospital discharge data can understate incidence because private-hospital coverage is low, while sampled hospital surveys have incomplete coverage and may count repeat admissions.[49][51]Mortality data may contain classification errors, and surveys without clinical examinations can underestimate hypertension, diabetes and hypercholesterolaemia.[60][61]The framework calls for autonomous-community agreement on standardised criteria and information sharing, but the supplied material does not set out a single formal accountability body or comprehensive reporting protocol.[48][26]

Costing & Financing

The strategy describes the substantial economic burden of ischaemic heart disease but does not provide a dedicated implementation budget, financing formula, funding-gap estimate or resource-mobilisation plan for the national strategy.[1][62]Estimated direct and indirect costs in Spain were approximately 2,000 million euros annually in 2003.[1]A related cost breakdown totals 1,948.89 million euros, comprising 1,221.45 million euros in indirect costs and 727.44 million euros in direct costs.[63][64]

• Identify indirect costs from permanent incapacity, temporary incapacity and premature mortality, alongside follow-up costs.[63]
• Identify direct costs from pharmaceuticals and hospitalisation.[64]
• Apply the human-capital approach to the reported cost distribution across autonomous communities and Ceuta and Melilla.[64]
• Use hospital reference costs for ischaemic-heart-disease activity coded C410–414 in the International Classification of Diseases, Ninth Revision, through the Minimum Basic Data Set and diagnosis-related groups; no monetary values are supplied.[65][50]
• Recognise resource requirements for emergency transport, defibrillation, electrocardiography, specialist catheterisation and angioplasty services, trained staff, monitoring facilities and diagnostic equipment, without quantified costs.[36][37]
• Support research through public agencies, industry and professional societies, while addressing the absence of dedicated research lines in primary-care and hospital budgets.[66]
• Establish a transparent National Health System research allocation in the range of thousandths of participating centres’ total budgets, with no fixed amount specified.[66]

The only quantified external quality-improvement financing example concerns the United States Quality Improvement Organizations programme, funded from public taxation through the Medicare Trust Fund at approximately 300 million US dollars, or about 5 US dollars per beneficiary annually.[41]“Class without Smoke” also received a 50% contribution from the European Commission’s Europe Against Cancer programme.[67]These examples do not constitute a Spanish implementation budget.[67][41]